Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TAO Synergies Inc.

Get SEC filing alerts via email and in your feed for TAO Synergies Inc.

TAOX

TAO Synergies Inc.

About TAO Synergies Inc.

Synaptogenix is a biopharmaceutical company focused on developing therapies for neurodegenerative and cognitive disorders, primarily Alzheimer's disease. Its core platform involves activating Protein Kinase C epsilon (PKCε) using Bryostatin-1, a natural product and synthetic derivatives, to promote synaptic regeneration and neuronal protection. The company advances drug candidates through preclinical and clinical testing, leveraging licensed technologies and strategic collaborations to address unmet medical needs in neurodegeneration.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TAO Synergies Inc.

1
1
TAO Synergies Inc. TAO Synergies Inc. Reports $388K Revenue and $4.25M Net Income for Quarter Ending March 31, 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
TAO Synergies Inc. TAO Synergies Inc. Shifts to Cryptocurrency Strategy, Reports $299K Revenue and $28.7M Net Loss

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
TAO Synergies Inc. TAO Synergies Inc. Reports Q3 2025 Financial Results with $3.9M Net Loss and First Revenue from TAO Token Staking

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TAO Synergies Inc. TAO Synergies Inc. Reports First Revenue from Digital Asset Staking, Faces Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TAO Synergies Inc. Synaptogenix Reports Net Income of $385,169 in Q1 2025, Significant Turnaround from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TAO Synergies Inc. Synaptogenix Reports Increased Net Losses of $12.8 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TAO Synergies Inc. Synaptogenix Reports Significant Net Loss and Decrease in Cash Reserves in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments